Cytosorbents (CTSO) CEO Phillip Chan Buys 200,000 Shares

What Happened Phillip P. Chan, CEO of Cytosorbents Corporation (CTSO), made an open-market purchase of 200,000 shares on September 4, 2026. The reported weighted-average price was $0.35 per share for a total cash outlay of about $70,000. This was a purchase (buy), which is generally more informative to investors than routine sales.

Key Details

• Transaction date: September 4, 2026 (reported on Form 4 filed September 9, 2026).
• Price: weighted average $0.35; actual purchases occurred at prices ranging from $0.3470 to $0.3599 (footnote 1).
• Amount purchased: 200,000 shares (open market).
• Reported holdings / related equity: footnote 3 states the reporting person owns 1,475,632 shares of common stock and additional RSUs (see footnote 2 and 3 for RSU detail). The filing itself notes the shares reported were not adjusted for the issuer’s reverse stock split on September 8, 2026 (footnote 4).
• Footnotes of note:
  • F1: Price shown is a weighted average; multiple trades in the range $0.3470–$0.3599.
  • F2/F3: Lists various RSUs that may convert on vesting/change-in-control and states 1,475,632 shares owned by the reporting person.
  • F4: Share counts/prices in this filing are not adjusted for the reverse split that occurred Sep 8, 2026.
• Timeliness: The Form 4 was filed five days after the trade (Sep 9 vs. Sep 4); Form 4s are generally due within two business days, so this filing was later than the standard reporting window, which can reduce the promptness of public disclosure.

Context

• This was a straight open-market purchase (code P). No options were exercised and no awards/gifts/tax withholdings were reported in connection with this transaction.
• Purchases by executives are often watched by retail investors as a signal of insider buying, but filings do not state the insider’s motivation. Note the reverse split adjustment caveat: reported share counts and per-share comparisons may change once adjusted for the Sep 8, 2026 reverse split.